The Marine Corps quietly directed its recruit depots to integrate male and female drill instructor teams at the platoon level in late 2023, and now the service is full steam ahead with the effort ...

Take a look inside the Marine One models used by modern presidents. Similar to Air Force One, any Marine Corps aircraft carrying the president of the United States uses the call sign Marine One.

In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $75.00. The company’s ...

Japan’s Supreme Court recently denied Okinawa Gov. Denny Tamaki’s final legal challenge to stop construction at a future Marine Corps airfield in the island’s north. The Tokyo court on ...

In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $65.00. The company’s ...

Shares of CRBP stock opened at $9.78 on Monday. The company’s fifty day simple moving average is $12.65 and its two-hundred day simple moving average is $27.00. Corbus Pharmaceuticals has a 52 ...

Military police and engineers from eight states are among the Army and Marine units the Pentagon is sending to the southern border this week while soldiers with the 82nd Airborne and 10th Mountain ...

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell ~12% in the premarket on Friday after the company announced data from its US and UK-conducted first-in-human dose escalation clinical study of ...

Shares of CRBP opened at $8.78 on Friday. The firm has a market cap of $106.94 million, a PE ratio of -1.87 and a beta of 2.63. Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month ...

Participants in HNSCC, cervical, and mUC tumors are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts. Price Action: CRBP stock is down 8.23% at $8.70 at the last check on Friday.

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc.(CRBP), has reported promising data for CRB-701 or SYS6002, a next-generation Nectin-4 targeting antibody-drug conjugate or ADC, at the 2025 ...